Updated First-line Osimertinib in Asian patients with Advanced EGFR-mutated Lung Cancer

被引：0
|
作者：
Tan, W. L. [1 ]
Tan, S. H. [1 ]
Tan, D. S. W. [1 ]
Lai, G. G. Y. [1 ]
Ang, M. -K. [1 ]
Jain, A. [1 ]
Kanesvaran, R. [1 ]
Rajasekaran, T. [1 ]
Saw, S. P. L. [1 ]
Teh, Y. L. [1 ]
Chan, J. [1 ]
Ng, Q. S. [1 ]
Lim, D. W. -T. [1 ]
机构：
[1] Natl Canc Ctr Singapore, Singapore, Singapore
来源：
JOURNAL OF THORACIC ONCOLOGY | 2023年 / 18卷 / 11期
关键词：
EGFR-mutated NSCLC; First-line Osimertinib; Asian patients;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
EP12.01-31
引用
收藏
页码：S652 / S653
页数：2
相关论文
共 50 条
  • [1] First-line osimertinib in patients with EGFR-mutated advanced non-small cell lung cancer
    Jeong, Byeong-Ho
    Um, Sang-Won
    ANNALS OF TRANSLATIONAL MEDICINE, 2018, 6 (03)
  • [2] First-Line Osimertinib in Asian Patients with Advanced EGFR-Mutant Lung Cancer
    Tan, W.
    Chua, B.
    Yin, D.
    Tan, S. H.
    Tan, D.
    Ang, M.
    Kanesvaran, R.
    Jain, A.
    Rajasekaran, T.
    Lai, G.
    Toh, C. K.
    Tan, E.
    Ng, Q. S.
    Lim, W.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) : S607 - S607
  • [3] Osimertinib as First-Line Treatment in EGFR-Mutated Non-Small-Cell Lung Cancer
    Popat, Sanjay
    NEW ENGLAND JOURNAL OF MEDICINE, 2018, 378 (02): : 192 - 193
  • [4] Cost-effectiveness of Osimertinib in the First-Line Treatment of Patients With EGFR-Mutated Advanced Non-Small Cell Lung Cancer
    Aguiar, Pedro N., Jr.
    Haaland, Benjamin
    Park, Wungki
    Tan, Pui San
    del Giglio, Auro
    Lopes, Gilberto de Lima, Jr.
    JAMA ONCOLOGY, 2018, 4 (08) : 1080 - 1084
  • [5] Real-World-Data on First-Line Therapy with Osimertinib in Patients with advanced EGFR-mutated NSCLC
    Griesinger, F.
    Nieva, J.
    Kim, Y.
    Cohen, A.
    Horvat, P.
    Lu, S.
    Taylor, A.
    Yu, N.
    Shenolikar, R.
    Shaw, S.
    PNEUMOLOGIE, 2021, 75 : S11 - S11
  • [6] Cost-effectiveness of lazertinib as first-line treatment in patients with EGFR-mutated advanced lung cancer
    Ku, Li-Jung Elizabeth
    Tsai, Jui-Hung
    Chen, Li-Jun
    Yang, Szu-Chun
    THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2025, 17
  • [7] Candidate mechanisms of acquired resistance to first-line osimertinib in EGFR-mutated advanced non-small cell lung cancer
    Chmielecki, Juliann
    Gray, Jhanelle E.
    Cheng, Ying
    Ohe, Yuichiro
    Imamura, Fumio
    Cho, Byoung Chul
    Lin, Meng-Chih
    Majem, Margarita
    Shah, Riyaz
    Rukazenkov, Yuri
    Todd, Alexander
    Markovets, Aleksandra
    Barrett, J. Carl
    Hartmaier, Ryan J.
    Ramalingam, Suresh S.
    NATURE COMMUNICATIONS, 2023, 14 (01)
  • [8] First-Line Management of EGFR-Mutated Advanced Lung Adenocarcinoma: Recent Developments
    Bin-Chi Liao
    Chia-Chi Lin
    James Chih-Hsin Yang
    Drugs, 2013, 73 : 357 - 369
  • [9] First-Line Management of EGFR-Mutated Advanced Lung Adenocarcinoma: Recent Developments
    Liao, Bin-Chi
    Lin, Chia-Chi
    Yang, James Chih-Hsin
    DRUGS, 2013, 73 (04) : 357 - 369
  • [10] Osimertinib in first-line treatment of advanced EGFR-mutated non-small-cell lung cancer: a cost-effectiveness analysis
    Aguilar-Serra, Javier
    Gimeno-Ballester, Vicente
    Pastor-Clerigues, Alfonso
    Milara, Javier
    Marti-Bonmati, Ezequiel
    Trigo-Vicente, Cristina
    Alos-Alminana, Manuel
    Cortijo, Julio
    JOURNAL OF COMPARATIVE EFFECTIVENESS RESEARCH, 2019, 8 (11) : 853 - 863
12345